Direct oral anticoagulant reversal: how, when and issues faced

References

• Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016;388:806–817.
   PubMed Web of Science ®Google Scholar
• Lip G, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117:1230–1239.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Lip GY. Stroke and bleeding risk assessment: where are we now? J Atr Fibrillation. 2014;6:49–57.
   Google Scholar
• Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172–1179.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;2016(18):1609–1678.
   Web of Science ®Google Scholar
• National institute for Health and Care Excellence. Atrial fibrillation: management. NICE guidelines [CG180]. Published date: June 2014. Last updated: August 2014. [cited 2017 Apr 20]. Available from: https://www.nice.org.uk/guidance/cg180# [Accessed 2017 Apr 15].
   Google Scholar
• Dzeshka MS, Lip GY. Antithrombotic and anticoagulant therapy for atrial fibrillation. Heart Fail Clin. 2016;12:257–271.
   PubMed Web of Science ®Google Scholar
• Sjogren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370–1377
   Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost. 2014;111:833–841.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Lip GY. Non-vitamin K oral anticoagulants in atrial fibrillation: where are we now? Trends Cardiovasc Med. 2015;25:315–336.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, Jjv M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl J Med. 2014;371:1464–1465.
   PubMed Web of Science ®Google Scholar
• Hillis C, Crowther MA. Acute phase treatment of VTE: anticoagulation, including non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015;113:1193–1202.
   PubMed Web of Science ®Google Scholar
• Schulman S, Singer D, Ageno W, et al. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost. 2017;117:1317–1325.
   PubMed Web of Science ®Google Scholar
• Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016;115:152–160.
   PubMed Web of Science ®Google Scholar
• Carmo J, Moscoso Costa F, Ferreira J, et al. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016;116:754–763.
   PubMed Web of Science ®Google Scholar
• Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114:1277–1289.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375:534–544.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost. 2017;117:1283–1288.
   PubMed Web of Science ®Google Scholar
• Pottegard A, Garcia Rodriguez LA, Poulsen FR, et al. Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark. Thromb Haemost. 2015;114:1064–1075.
   PubMed Web of Science ®Google Scholar
• Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997–1011.
   PubMed Web of Science ®Google Scholar
• Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26:1471–1477.
   PubMed Web of Science ®Google Scholar
• Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880–884.
   PubMed Web of Science ®Google Scholar
• Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975–986.
   PubMed Web of Science ®Google Scholar
• Hagii J, Tomita H, Metoki N, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke. 2014;45:2805–2807.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141–2147.
   PubMed Web of Science ®Google Scholar
• Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325–2332.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68:2597–2604.
   PubMed Web of Science ®Google Scholar
• Barra ME, Fanikos J, Connors JM, et al. Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med. 2016;129:1198–1204.
   PubMed Web of Science ®Google Scholar
• Kittelson JM, Steg PG, Halperin JL, et al. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2016;116:544–553.
   PubMed Web of Science ®Google Scholar
• Michalski F, Tittl L, Werth S, et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost. 2015;114:1076–1084.
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost. 2016;115:31–39.
   PubMed Web of Science ®Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209–218.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Camm AJ, Coleman CI, et al. Rivaroxaban real-world evidence: validating safety and effectiveness in clinical practice. Thromb Haemost. 2016;116:S13–S23.
   PubMed Web of Science ®Google Scholar
• Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016;115:939–949.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ebertz F, Forster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015;113:1247–1257.
   PubMed Web of Science ®Google Scholar
• Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114:1290–1298.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584–589.
   PubMed Web of Science ®Google Scholar
• Lip GY, Skjoth F, Nielsen PB, et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015;114:826–834.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Lane DA, Buller H, et al. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost. 2013;110:1074–1079.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Lip GY. Specific risk scores for specific purposes: use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation. Thromb Res. 2014;134:217–218.
   PubMed Web of Science ®Google Scholar
• Lip GY, Lin HJ, Hsu HC, et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol. 2013;168:1832–1836.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60:861–867.
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost. 2017;117. DOI: https://doi.org/10.1160/TH17-07-0478
   Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Lane DA, Lip GY. Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2 -VASc, R2 CHADS2, HAS-BLED, ATRIA, and more). Clin Cardiol. 2014;37:634–644.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Pollack CV Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015;114:1113–1126.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Chatelain B, Chatelain C, et al. Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost. 2016;115:368–381.
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016;116:879–890.
   PubMed Web of Science ®Google Scholar
• Niessner A, Tamargo J, Morais J, et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017;38:1710–1716.
   PubMed Web of Science ®Google Scholar
• Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011;106:429–438.
   PubMed Web of Science ®Google Scholar
• Brekelmans MPA, Ginkel KV, Daams JG, et al. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis. 2017;44:118–129.
   PubMed Web of Science ®Google Scholar
• Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154:529–540.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Schurer J, Kink-Eiband M, et al. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology. 2014;120:1429–1440.
   PubMed Web of Science ®Google Scholar
• Honickel M, Maron B, Van Ryn J, et al. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thromb Haemost. 2016;115:271–284.
   PubMed Web of Science ®Google Scholar
• Lambourne MD, Eltringham-Smith LJ, Gataiance S, et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost. 2012;10:1830–1840.
   PubMed Web of Science ®Google Scholar
• Perzborn E, Heitmeier S, Laux V, et al. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014;133:671–681.
   PubMed Web of Science ®Google Scholar
• Godier A, Miclot A, Le Bonniec B, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012;116:94–102.
   PubMed Web of Science ®Google Scholar
• Levi M, Moore KT, Castillejos CF, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014;12:1428–1436.
   PubMed Web of Science ®Google Scholar
• Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594–3599.
   PubMed Web of Science ®Google Scholar
• Zhou W, Zorn M, Nawroth P, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44:771–778.
   PubMed Web of Science ®Google Scholar
• Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015;131:82–90.
   PubMed Web of Science ®Google Scholar
• Ageno W, Buller HR, Falanga A, et al. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost. 2016;116:1003–1010.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124:955–962.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35:1873–1880.
   PubMed Web of Science ®Google Scholar
• Baumann Kreuziger LM, Reding MT. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Thromb Res. 2013;132:e161–3.
   PubMed Web of Science ®Google Scholar
• Schiele F, Van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–3562.
   PubMed Web of Science ®Google Scholar
• Schmohl M, Glund S, Harada A, et al. Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost. 2017;117:269–276.
   PubMed Web of Science ®Google Scholar
• Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–951.
   PubMed Web of Science ®Google Scholar
• Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680–690.
   PubMed Web of Science ®Google Scholar
• Glund S, Stangier J, Schmohl M, et al. Abstract 17765: a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation. 2013;128:A17765.
   Web of Science ®Google Scholar
• Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014;124:344.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Schmoll M, Pillu H, et al. Abstract 18403: effect of dabigatran on the ability to generate fibrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy volunteers: an exploratory marker of blood loss. Circulation. 2014;130:A18403.
   Web of Science ®Google Scholar
• Grottke O, Honickel M, van Ryn J, et al. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. 2015;66:1518–1519.
   PubMed Web of Science ®Google Scholar
• Honickel M, Treutler S, van Ryn J, et al. Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost. 2015;113:728–740.
   PubMed Web of Science ®Google Scholar
• Na S-Y, Mracsko E, van Ryn J, et al. Idarucizumab improves outcome in murine brain hemorrhage related to dabigatran. Ann Neurol. 2015;78:137–141.
   PubMed Web of Science ®Google Scholar
• Honickel M, Spronk HM, Rossaint R, et al. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding. Thromb Haemost. 2017;117:1370–1378.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431–441.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Praxbind summary of product characteristics. First published December 1, 2015. Last updated August 2, 2017. [cited 2017 Sept 10]. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003986/WC500197462.pdf [Accessed 2017 Sept 9].
   Google Scholar
• Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–451.
   PubMed Web of Science ®Google Scholar
• Hollenbach S, Lu G, DeGuzman F, et al. Abstract 14657: andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model - only andexanet reverses markers of fXa-mediated anticoagulation. Circulation. 2014;130:A14657.
   Web of Science ®Google Scholar
• Hollenbach SJ, Lu G, Tan S, et al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model. Blood. 2012;120:3414.
   Web of Science ®Google Scholar
• Hollenbach S, Tan S, Deguzman F, et al. PRT064445 reverses rivaroxaban induced anticoagulation in a rabbit liver laceration “treatment” model. European Heart Journal. 2013;34:P241–P.
   Web of Science ®Google Scholar
• Crowther M, Kitt M, McClure M, et al. Abstract 10: randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors. Arterioscler Thromb Vasc Biol. 2013;33:A10.
   Google Scholar
• Vandana M, Michael K, Genmin L, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for fXa inhibitors. Blood. 2013;122:3636.
   Web of Science ®Google Scholar
• Crowther M, Kitt M, Lorenz T, et al. A phase 2 randomized, double-blind, placebocontrolled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemostasis. 2013;11:30.
   Web of Science ®Google Scholar
• Crowther M, Levy GG, Lu G, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood. 2014;124:4269.
   Web of Science ®Google Scholar
• Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–2424.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Milling TJ Jr., Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–1141.
   PubMed Web of Science ®Google Scholar
• Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of Per977. J Thromb Haemostasis. 2013;11:75.
   PubMed Web of Science ®Google Scholar
• Laulicht B, Laulicht B, Laulicht B, et al. Abstract 11395: small molecule antidote for anticoagulants. Circulation. 2012;126:A11395.
   Web of Science ®Google Scholar
• Bakhru S, Laulicht B, Jiang X, et al. Abstract 18809: PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation. 2013;128:A18809.
   Web of Science ®Google Scholar
• Bakhru S, Laulicht B, Jiang X, et al. Abstract 19361: reversal of anticoagulant-induced bleeding in external and internal bleeding models by PER977, a small molecule anticoagulant antidote. Circulation. 2014;130:A19361.
   Web of Science ®Google Scholar
• Lu G, Kotha J, Cardenas JM, et al. Abstract 18218: in vitro characterization of andexanet alfa (PRT064445), a specific fXa inhibitor antidote versus aripazine (PER977), a non-specific reversal agent. Circulation. 2014;130:A18218.
   Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–2142.
   PubMed Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117:238–245.
   PubMed Web of Science ®Google Scholar
• Sullivan DW Jr., Gad SC, Laulicht B, et al. Nonclinical safety assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol. 2015;34:308–317.
   PubMed Web of Science ®Google Scholar
• Costin JC, Laulicht B, Bakhru S, et al. PER977 reverses low molecular weight heparin in addition to IIa and Xa new oral anticoagulants. J Am Coll Cardiol. 2015;65:A2056.
   Web of Science ®Google Scholar
• Ansell JE, Laulicht BE, Bakhru SH, et al. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res. 2016;146:113–118.
   PubMed Web of Science ®Google Scholar
• Perosphere, Inc. Study of PER977 administered to subjects with steady state edoxaban dosing and re-anticoagulation with edoxaban. NLM Identifier: NCT02207257; 2014. [cited 2017 Jul 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02207257 [Accessed 2017 July 10].
   Google Scholar
• Perosphere, Inc. Study of ciraparantag administered to volunteers anticoagulated with rivaroxaban, measure clotting times using WBCT. NLM Identifier: NCT03172910; 2017. [cited 2017 Jul 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03172910 [Accessed 2017 July 10].
   Google Scholar
• Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017;117:1448–1454.
   PubMed Web of Science ®Google Scholar
• Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. Jama. 2015;313:824–836.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Larsen TB, Skjoth F, et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation. 2015;132:517–525.
   PubMed Web of Science ®Google Scholar
• Loewen PS, Ji AT, Kapanen A, et al. Patient values and preferences for antithrombotic therapy in atrial fibrillation. A narrative systematic review. Thromb Haemost. 2017;117:1007–1022.
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C, Hillis C, Monreal M, et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost. 2015;114:819–825.
   PubMed Web of Science ®Google Scholar
• Majeed A, Wallvik N, Eriksson J, et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost. 2017;117:491–499.
   PubMed Web of Science ®Google Scholar
• Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014;113:662–668.
   PubMed Web of Science ®Google Scholar
• Staerk L, Lip GY, Olesen JB, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015;351:h5876.
   PubMed Web of Science ®Google Scholar